Study on Mesenchymal Stem Cell Therapy for Female Premature Ovarian Failure

  • Xiong Gao* Hunan Central South stem cell Hospital
  • Li Peng The Second Xiangya Hospital of Central South University
  • Ruoling Mo Hainan Vocational University of Science and Technology
  • Miaowei Wang Department of Rehabilitation Medicine, West China Hospital
  • Xing Jin Northern Jiangsu People’s Hospital
Keywords: Mesenchymal Stem Cells; Premature Ovarian Failure; Clinical Translation; Paracrine Effects

Abstract

Premature Ovarian Failure (POF) refers to ovarian dysfunction occurring in women before the age of 40, characterized by amenorrhea, infertility, and hypoestrogenic symptoms, which severely impairs patients’ reproductive health and quality of life. Traditional treatments such as Hormone Replacement Therapy (HRT) can only alleviate symptoms but cannot reverse ovarian function decline. Mesenchymal Stem Cells (MSCs) have emerged as a research hotspot in regenerative therapy for POF due to their multipotent differentiation potential, immunomodulatory properties, and paracrine characteristics. This article systematically reviews the biological characteristics of MSCs derived from bone marrow, umbilical cord, adipose tissue, and menstrual blood, and deeply explores their core mechanisms in repairing ovarian function, including inhibiting cell apoptosis, regulating the immune microenvironment, promoting angiogenesis, and exerting paracrine effects. It further analyzes the efficacy differences of various transplantation routes in clinical applications and existing challenges, and prospects breakthrough directions in technologies such as biomaterial-combined transplantation and gene editing. This review provides a theoretical reference for basic research and clinical translation of MSCs-based therapy for POF.

References

[1] Zou, Y. H., Ding, X. P., & Zheng, Y. F. (2025). Current status of research on stem cell application in premature ovarian failure. Chinese Journal of Birth Health and Heredity, 33(2), 471-477.

[2] Li, Y. Q., Gong, X. C., & Xing, Y. Y. (2024). Study on the therapeutic effect of exosomes derived from adipose-derived mesenchymal stem cells on premature ovarian failure. Journal of Reproductive Medicine, 33(12), 1627-1634.

[3] Liu, Y. Y., Ma, Y. Y., Huang, X. H., & Zhang, J. K. (2025). Mechanisms of mesenchymal stem cells from different sources in the

treatment of premature ovarian failure. Chinese Journal of Tissue Engineering Research, 29(13), 2764-2773.

[4] Chang, M. Y. (2024). Study on the improvement effect and potential mechanisms of mesenchymal stem cells on premature ovarian

failure [Master’s thesis]. Xinxiang Medical University.

[5] Liu, Y. Y., He, X. L., & Tian, X. F. (2023). Research progress on mesenchymal stem cell therapy for premature ovarian failure. Fuer

Jiankang Daokan (Guide of Women and Children Health), 2(18), 18-20+29.

Published
2025-11-18
Issue
Vol 14 No 3 (2025)
Section
Review Article

Authors submitting to USP journals agree to publish their manuscript under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0) where authors agree to allow third parties to share their work (copy, distribute, transmit) and to adapt it, under the condition that the authors are given credit, and that in the event of reuse or distribution, the terms of this license are made clear

Authors retain copyright of their work, with first publication rights (online and print) granted to Universe Scientific Publishing or the owner of the journal in question.